Filing Details
- Accession Number:
- 0001447362-24-000187
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-19 16:04:09
- Reporting Period:
- 2024-11-15
- Accepted Time:
- 2024-11-19 16:04:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1447362 | Castle Biosciences Inc | CSTL | Services-Medical Laboratories (8071) | 770701774 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1782815 | Frank Stokes | C/O Castle Biosciences, Inc. 505 S. Friendswood Drive, Suite 401 Friendswood TX 77546 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-11-15 | 6,123 | $29.87 | 31,623 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-11-15 | 800 | $30.40 | 30,823 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 13, 2024.
- This transaction was executed in multiple trades at prices ranging from $29.40 to $30.35, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $30.400 to $30.425, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.